Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 4/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 4/20 | 0.43 |
| ▸ | MARK3 | P27448 | 4/20 | 0.43 |
| ▸ | AXL | P30530 | 4/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.43 |
| ▸ | CLK2 | P49760 | 4/20 | 0.43 |
| ▸ | GSK3A | P49840 | 4/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | BLK | P51451 | 4/20 | 0.43 |
| ▸ | NEK4 | P51957 | 4/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 4/20 | 0.43 |
| ▸ | CAMK2G | Q13555 | 4/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8940605 | 0.94 | BTK (0.38) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940470 | 0.94 | DYRK1A (0.45) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940562 | 0.91 | BTK (0.41) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940737 | 0.89 | NTRK1 (0.44) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940364 | 0.88 | BTK (0.39) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940585 | 0.88 | BTK (0.52) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940514 | 0.88 | BTK (0.42) | BTK | |
| SCHEMBL8941182 | 0.88 | DYRK1A (0.49) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8941173 | 0.87 | BTK (0.37) | DYRK3PRKD3MAP4K4NTRK1CDK1 | |
| SCHEMBL8940361 | 0.87 | BTK (0.41) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | DYRK3 539/4885PRKD3 43/4885MAP4K4 154/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | DYRK3 539/4885PRKD3 43/4885MAP4K4 154/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | DYRK3 539/4885PRKD3 43/4885MAP4K4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.